Trials / Completed
CompletedNCT01721746
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-936558 | |
| DRUG | Dacarbazine | |
| DRUG | Carboplatin | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2012-12-21
- Primary completion
- 2016-02-16
- Completion
- 2020-12-29
- First posted
- 2012-11-06
- Last updated
- 2022-04-19
- Results posted
- 2017-03-22
Locations
95 sites across 14 countries: United States, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01721746. Inclusion in this directory is not an endorsement.